{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:03:53Z","timestamp":1790741033237,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102994","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:44:22Z","timestamp":1787802262000},"page":"102994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Spatially-resolved pharmaco-ecology of immunotherapy resistance in lung adenocarcinoma: Single-cell and spatial transcriptomics for mechanism-matched combination therapies"],"prefix":"10.1016","volume":"72","author":[{"given":"Yiming","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0001","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol."},{"issue":"7511","key":"10.1016\/j.tranon.2026.102994_bib0002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.tranon.2026.102994_bib0003","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.tranon.2026.102994_bib0006","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0007","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus Pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.tranon.2026.102994_bib0008","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0009","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.tranon.2026.102994_bib0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0013","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/1078-0432.CCR-19-2931","article-title":"Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102994_bib0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI. Insight."},{"issue":"7693","key":"10.1016\/j.tranon.2026.102994_bib0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0016","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.tranon.2026.102994_bib0017","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0018","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"issue":"7870","key":"10.1016\/j.tranon.2026.102994_bib0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1573","article-title":"Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma","volume":"14","author":"Xie","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.102994_bib0021","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-induced evolution of Human lung cancer revealed by single-cell RNA sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0022","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.tranon.2026.102994_bib0024","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of Human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.tranon.2026.102994_bib0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102994_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0027","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in Human lung tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.tranon.2026.102994_bib0029","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102994_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1634\/theoncologist.2016-0150","article-title":"Mixed responses to systemic therapy revealed potential genetic heterogeneity and poor survival in patients with non-small cell lung cancer","volume":"22","author":"Dong","year":"2017","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.tranon.2026.102994_bib0032","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0033","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.tranon.2026.102994_bib0034","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.tranon.2026.102994_bib0035","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 Deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.tranon.2026.102994_bib0036","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.tranon.2026.102994_bib0037","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR mutations predict tumor immune profile and the response to Anti-PD-1 in lung adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.tranon.2026.102994_bib0038","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0039","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"8038","key":"10.1016\/j.tranon.2026.102994_bib0040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.tranon.2026.102994_bib0041","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41588-025-02351-7","article-title":"Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer","volume":"57","author":"Aung","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0042","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0043","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0044","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"issue":"6657","key":"10.1016\/j.tranon.2026.102994_bib0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.tranon.2026.102994_bib0046","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.21037\/tlcr-2025-244","article-title":"Single-cell and spatial transcriptomics profile the interaction Of spp1(+) macrophages and FAP(+) fibroblasts in non-small cell lung cancer","volume":"14","author":"Xiao","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"issue":"9","key":"10.1016\/j.tranon.2026.102994_bib0047","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.21037\/tlcr-2025-912","article-title":"Single-cell and spatial analysis reveals macrophage-T cell crosstalk in non-small cell lung cancer immunosuppression","volume":"14","author":"Zhu","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2026.102994_bib0048","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0049","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.tranon.2026.102994_bib0050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41590-024-01792-2","article-title":"Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy","volume":"25","author":"Chen","year":"2024","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0051","article-title":"Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures","volume":"6","author":"Peyraud","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0052","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0053","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.tranon.2026.102994_bib0054","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2026.102994_bib0056","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0057","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.tranon.2026.102994_bib0058","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0059","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial-mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0060","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1038\/s41467-019-13441-6","article-title":"Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution","volume":"10","author":"Karacosta","year":"2019","journal-title":"Nat. Commun."},{"issue":"7702","key":"10.1016\/j.tranon.2026.102994_bib0061","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","article-title":"Identification of the tumour transition states occurring during EMT","volume":"556","author":"Pastushenko","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.tranon.2026.102994_bib0062","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","article-title":"Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer","volume":"171","author":"Puram","year":"2017","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.tranon.2026.102994_bib0063","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","article-title":"Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma","volume":"22","author":"Lou","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0064","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1038\/s41598-018-21061-1","article-title":"Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)","volume":"8","author":"Chae","year":"2018","journal-title":"Sci. Rep."},{"issue":"277","key":"10.1016\/j.tranon.2026.102994_bib0065","doi-asserted-by":"crossref","first-page":"277ra30","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0066","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0067","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.tranon.2026.102994_bib0068","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.tranon.2026.102994_bib0069","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","article-title":"Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing","volume":"24","author":"Guo","year":"2018","journal-title":"Nat. Med."},{"issue":"7802","key":"10.1016\/j.tranon.2026.102994_bib0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0071","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"7822","key":"10.1016\/j.tranon.2026.102994_bib0072","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4(+) T cells to induce anti-Tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0073","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s13402-025-01052-x","article-title":"Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer","volume":"48","author":"Elfving","year":"2025","journal-title":"Cell Oncol."},{"issue":"6574","key":"10.1016\/j.tranon.2026.102994_bib0074","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"issue":"7764","key":"10.1016\/j.tranon.2026.102994_bib0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.tranon.2026.102994_bib0076","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.tranon.2026.102994_bib0077","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","article-title":"Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.102994_bib0078","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.immuni.2016.10.021","article-title":"Transcriptional landscape of Human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells","volume":"45","author":"De Simone","year":"2016","journal-title":"Immunity"},{"issue":"87","key":"10.1016\/j.tranon.2026.102994_bib0079","doi-asserted-by":"crossref","first-page":"eadg1487","DOI":"10.1126\/sciimmunol.adg1487","article-title":"Lung tumor-infiltrating T(reg) have divergent transcriptional profiles and function linked to checkpoint blockade response","volume":"8","author":"Dykema","year":"2023","journal-title":"Sci. Immunol."},{"issue":"35","key":"10.1016\/j.tranon.2026.102994_bib0080","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0081","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0082","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0083","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"issue":"699","key":"10.1016\/j.tranon.2026.102994_bib0084","doi-asserted-by":"crossref","first-page":"eadh8005","DOI":"10.1126\/scitranslmed.adh8005","article-title":"Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer","volume":"15","author":"Herzog","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0085","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-21-2649","article-title":"Association of PD-1\/PD-L1 Co-location with immunotherapy outcomes in non-small cell lung cancer","volume":"28","author":"Gavrielatou","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2026.102994_bib0086","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","article-title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer","volume":"24","author":"Park","year":"2023","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102994_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107585","article-title":"Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma","volume":"26","author":"Griesinger","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0088","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.tranon.2026.102994_bib0089","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41588-024-01883-8","article-title":"MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution","volume":"56","author":"Puttick","year":"2024","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.tranon.2026.102994_bib0090","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s43018-022-00466-y","article-title":"Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80","volume":"3","author":"Shahbandi","year":"2022","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102994_bib0091","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"7791","key":"10.1016\/j.tranon.2026.102994_bib0092","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.tranon.2026.102994_bib0093","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.tranon.2026.102994_bib0094","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/2159-8290.CD-21-1658","article-title":"The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma","volume":"12","author":"Hao","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0095","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s42003-022-04356-y","article-title":"Regulatory T cells infiltrate the tumor-induced tertiary lympho\u00efd structures and are associated with poor clinical outcome in NSCLC","volume":"5","author":"Devi-Marulkar","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tranon.2026.102994_bib0096","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102994_bib0097","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.tranon.2026.102994_bib0098","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/PAI.0000000000000698","article-title":"Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-Small cell lung carcinomas","volume":"26","author":"Bigras","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0099","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","article-title":"Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer","volume":"9","author":"Jia","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12672-025-02269-w","article-title":"Single-cell profiling uncovers the intricate pathological niche diversity in brain, lymph node, bone, and adrenal metastases of lung cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102994_bib0101","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00262-020-02840-0","article-title":"Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape","volume":"70","author":"Song","year":"2021","journal-title":"Cancer Immunol. Immunther."},{"issue":"1","key":"10.1016\/j.tranon.2026.102994_bib0102","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13059-020-02175-0","article-title":"Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity","volume":"21","author":"Lee","year":"2020","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102994_bib0103","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1158\/2767-9764.CRC-22-0050","article-title":"Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential interlesion immune infiltration","volume":"2","author":"Morinaga","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"12","key":"10.1016\/j.tranon.2026.102994_bib0104","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunol. Immunther."},{"issue":"10","key":"10.1016\/j.tranon.2026.102994_bib0105","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102994_bib0106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/tlcr-22-106","article-title":"Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients","volume":"11","author":"Yue","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2026.102994_bib0107","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","article-title":"Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer","volume":"14","author":"Enfield","year":"2024","journal-title":"Cancer Discov."},{"issue":"16","key":"10.1016\/j.tranon.2026.102994_bib0108","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2026.102994_bib0109","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.3390\/cancers16244145","article-title":"Novel spatial approaches to dissect the lung cancer immune microenvironment","volume":"16","author":"Lubo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102994_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003890","article-title":"Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies","volume":"10","author":"Larroquette","year":"2022","journal-title":"J. ImmunOther Cancer"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600330X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600330X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:44:07Z","timestamp":1790739847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332600330X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":110,"alternative-id":["S193652332600330X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102994","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatially-resolved pharmaco-ecology of immunotherapy resistance in lung adenocarcinoma: Single-cell and spatial transcriptomics for mechanism-matched combination therapies","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102994"}}